Atty Docket No. 015542-002330US

PTO FAX NO.: 703-308-4242

ATTENTION: Examiner D. Lukton
Group Art Unit 1653

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER D. Lukton

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following Preliminary Amendment, including 5 pages, in re Application of Green et al., Serial No. 09/506,430, filed February 17, 2000, for PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 6

Dated: April5, 2001

Dana Kane

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: (415) 576-0200/Fax: (415) 576-0300

SF 150004 v1
SF 150004 v1

Supp. Amdt
10/C

I hereby certify that this correspondence is being sent by facsimile transmission to:

at Fax No.: 1-703-308-4242

On 4/5/01

TOWNSEND and TOWNSEND and CREW LLP

By: [signature]

PATENT
Attorney Docket No.: 15542-002330US
Client Reference No.: 121

Linda

FAX RECEIVED 4/12/01

APR 05 2001

GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Lukton, David
Green *et al.*	Art Unit: 1653
Application No.: 09/506,430	PRELIMINARY AMENDMENT
Filed: February 17, 2000	
For: PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF	

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

18. (New) A method of inhibiting neovascularization in a subject in need thereof comprising:

administering to said subject a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and an amount of a compound effective to inhibit neovascularization with the formula of R'-Glu-Trp-R" or pharmaceutically acceptable salts thereof,

wherein R' and R" is absent or a moiety independently selected from the group consisting of an amide, an imide, an ester, an anhydride, an ether, a methyl-alkyl ester, an ethyl-alkyl ester, an alkyl group, and an aryl group,